REVISTA BRASILEIRA DE REUMATOLOGIA, cilt.54, sa.5, ss.356-359, 2014 (SCI-Expanded)
Introduction: Colchicine is the mainstay for the treatment of FMF, which is an auto- inflammatory disease mainly with relapsing polyserositis. Despite daily doses of 2 mg or more each day, approximately 5% to 10% of the patients continue to suffer from its attacks. In this study, we aimed to investigate the depression and attack features in patients with FMF who have colchicine resistance (CR).